Martínez ÁDR, Santos GH, Reyes CS

Language: Spanish
References: 12
Page: 44-52
PDF size: 101.91 Kb.

ABSTRACT

Objective: to characterize the oncological patients who present with post chemotherapy febrile neutropenia and were admitted to the Institute of Oncology and Radiobiology in the period of January to May, 2015.
Methods: a descriptive cross-sectional study of a sample of 36 patients. Their medical histories were checked from which the analyzed variables were taken.
Results: females predominated in the study (61,1 %). Among the oncological diseases, non-Hodgkin lymphomas (25,0 %) prevailed whereas the cytostatic drugs found related to neutropenia were carboplatin, paclitaxel, ifosfamide and etoposide. The hematological recovery was reached in most cases before 72 hours and a lot of patients (72, 2 %) were classified as low risk neutropenia according to the Multinational Association for Supportive Care criteria.
Conclusions: in the study sample, the febrile neutropenia increases with the age and with hematopoietic diseases whereas chemotherapy schemes are based on high dose cytostatic agents.

REFERENCES

1. Bodey GP, Buckley M, Sathe YS. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-40.

2. Rosenberg PS, Alter BP, Bolyard AA. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term GCSF therapy. Blood. 2006;107:4628-35.

3. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004;39(Suppl 1):S25-31.

4. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39(Supl 1):32-7.

5. Vidal L, Paul M, Ben I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: A systematic review and meta-analysis of randomized trials. J Antimicrob Chemother. 2004;54:29-37.

6. de Naurois J, Novitzky-Basso I, Gill MJ, Marti F, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of Oncology. 2010;21 (Supplement 5):252-256.

7. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clinical Practice Guideline. Clin Infect Dis. 2011 Feb 15;52(4):e56-93.

8. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 2013; 31(6):794-810.

9. André S, Taboulet P, Elie C, Milpied N, Nahon M, Kierzek G, et al. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. André et al. Critical Care. 2010;14(2):R68.

10. Lami Casaus L, Arbesú Michelena MA, Alsina Sarmiento S, Brito Iglesia R. Aparición de episodios de neutropenia febril tras la quimioterapia citostática en el paciente oncológico. Rev Cubana Farm. 2009;43(4):68-73.

11. Paul M, Soares-Weiser K, Leibovici L. β lactam monotherapy versus β lactamaminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003;326:1111-20.

12. Rabagliati R, Fuentes G, Orellana E, Oporto J, Domínguez I, Benítez R, et al. Etiología de episodios de neutropenia febril en pacientes adultos con cáncer hematológico y de órganos sólidos en el Hospital Clínico Universidad Católica, Santiago-Chile. Rev Chil Infect. 2009;26(2):106-113.